Biopharmaceutical company ARS Pharmaceuticals Inc (Nasdaq:SPRY) announced on Monday that the European Commission has approved EURneffy (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis).

EURneffy is the first needle-free adrenaline treatment option in the EU, offering a more convenient and accessible alternative for adults and children with severe allergies.

It represents the first novel adrenaline delivery method in more than three decades, according to Richard Lowenthal, co-founder, president and CEO of ARS Pharma.

ARS Pharma anticipates that EURneffy will be available to patients in certain European Union member states in the fourth quarter of 2024.